Gonadotropin-releasing hormone and kisseptin-10 regulate nuclear receptor subfamily 5 group a member 1/catenin beta 1/ nuclear receptor subfamily 0 group B member 1 activity in female rat anterior pituitary gland

In this study, we tested the hypothesis that modulation of endogenous gonadotropin-releasing hormone (Gnrh) neuronal network activity alters the mRNA expression of nuclear receptor subfamily 5 group A member 1 (Nr5a1), through one of the component of Wnt pathway signaling - catenin beta 1 (Ctnnb1) (its co-activator), and its co-repressor nuclear receptor subfamily 0, group B member 1 (Nr0b1) in the female rat pituitary gland in vivo. Adult ovariectomized rats were given a serial infusion of Gnrh, kisspeptin-10, Gnrh + Gnrh antagonist (Antide), or kisspeptin-10 + kisspeptin antagonist (kisspeptin-234) into the third ventricle of the brain. The anterior pituitary and blood was used to mRNA and protein expression analysis. We demonstrated that Gnrh up-regulates Nr5a1 mRNA expression in the anterior pituitary and induces NR5A1 depletion in gonadotropes. Gnrh administration increased both Ctnnb1 mRNA expression and protein synthesis, and induced activation of cellular Ctnnb1 via translocation from the gonadotropes cytoplasm to nucleus. After kisspeptin-10 treatment, up-regulation of Nr0b1 mRNA and protein expression in the anterior pituitary was observed. These data indicate that Gnrh-neuron-mediated network activity alters Nr5a1 gene transcription and translation in gonadotrope cells and this effect may result from the changes induced in the Ctnnb1 and Nr0b1 gene/protein expression balance.

Pituitary galaninergic system activity in female rats: the regulatory role of gonadal steroids

The well-recognized sensitivity of the galanin gene in the anterior pituitary gland to estrogen suggests that estrogen receptor activity may influence the galaninergic system through modulation of galanin receptor (GALR) gene expression. Here, we evaluated the following: (i) the effects of estrogen on GALR mRNA expression; (ii) the estrogen receptor subtype that is specifically involved in this activity; and (iii) the effects of progesterone in the absence or presence of estrogen on galanin concentration in anterior pituitary gland. In the first experiment, ovariectomized 4-month-old rats were pre-treated subcutaneously with 17β-estradiol (3 x 20 μg), the ESR1 (ERα) agonist propyl pyrazole triol (PPT) (3 x 5 mg), and the ESR2 (ERβ) agonist diarylpropionitrile (DPN) (3 x 0.5 mg). In the second experiment, 4-month-old ovariectomized females received daily subcutaneous injections of 17β-estradiol (3 x 20 μg), progesterone (2 x 5 mg), or combined estradiol (3 x 20 μg) and progesterone (2 x 5 mg). Anterior pituitaries were excised the day after the final 17β-estradiol injection (experiment I) and 1 hour after receiving the second progesterone dose. Relative GALR1, GALR2, and GALR3 mRNA expression was evaluated using quantitative real-time PCR, and pituitary galanin concentration was determined using a specific radioimmunoassay. The results revealed that estrogen predominantly induced a 5-fold increase in GALR3 gene transcription. To a lesser extent, 17β-estradiol also increased GALR1 mRNA expression, but had no effect on GALR2 mRNA levels. The estrogen-induced increase in GALR3 gene expression occurred exclusively through ESR1 activation. The increase in GALR1 gene expression occurred through activation of both estrogen receptor subtypes, but the ESR2 subtype was predominantly involved. Furthermore, the results revealed that progesterone regulates the activity of the pituitary galaninergic system by facilitating estradiol-induced galanin synthesis in the female rat anterior pituitary gland.